Scientists have discovered a new benefit to Novo Nordisk’s weight-loss drug Wegovy: It can cut heart-related deaths by 20%, drugmaker reports

a box of wegovy injectables (Credit: Michael Siluk—UCG/Universal Images Group/Getty Images)

The Danish pharma giant Novo Nordisk has found itself at the center of the booming weight-loss industry with its drugs Wegovy and Ozempic taking the world by storm. 

But its benefits stretch beyond helping obese patients shed weight—it also cuts the risk of death associated with heart-related events by 20%, according to new data presented at the American Heart Association and published in the New England Journal of Medicine on Saturday.